Start the conversation
Private Briefing subscriber D.K. wrote to me late Monday and posed this question.
Greetings, Bill, from Tacoma, Washington. Please share your educated opinion on the three-month extension the FDA has apparently just announced for its review of Delcath System's new liver cancer treatment. - D.K.
Great question, D.K.
So let's take a look.
Our most recent recommendation of the New York-based Delcath Systems Inc. (Nasdaq: DCTH) was made in the research report "Buy With the Smart Money." We originally released that report back on Sept. 12, 2012, and have updated it several times since.
In our most recent update - late last week, in fact - we told you that the stock had been surging as several key deadlines in the drug-approval process drew near.
Then came Monday's disclosure, which is what D.K. and others are asking about.
This is premium content for Private Briefing subscribers only.